About me
Emily Nieves is the co-founder and CEO of Delineate, a seed-stage startup partnering with pharmaceutical companies to accelerate Model-Informed Drug Development workflows through advanced AI techniques. Prior to founding Delineate, Emily pursued graduate studies in Biological Engineering at MIT, where her research focused on hybrid AI and scientific machine learning algorithms. Her industry experience includes engagements with leading pharmaceutical organizations such as Pfizer and AstraZeneca, where she developed Quantitative Systems Pharmacology and machine learning models across therapeutic areas including the cardiorenal system, metabolism, and cell therapies. Emily holds a BS in Biological Engineering from the University of Georgia.
